

Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Drug Submission Status

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

| Manufacturer | Product | Reference Product | Generic Name | Strength | Dosage Form | DIN |
|--|--------------------|-------------------|------------------------------|----------|-------------|----------|
| Genmed, A Division of Pfizer Canada Inc. | GD-Azithromycin | Zithromax | azithromycin | 250mg | FC tablet | 02274531 |
| Patriot, A Division of Janssen Inc. | Pat-Galantamine ER | Reminyl ER | galantamine hydrobromide | 8mg | ER capsule | 02316943 |
| Patriot, A Division of Janssen Inc. | Pat-Galantamine ER | Reminyl ER | galantamine hydrobromide | 16mg | ER capsule | 02316951 |
| Patriot, A Division of Janssen Inc. | Pat-Galantamine ER | Reminyl ER | galantamine hydrobromide | 24mg | ER capsule | 02316978 |
| Pharmascience Inc. | Pms-Ramipril-HCTZ | Altace-HCT | ramipril/hydrochlorothiazide | 5mg/25mg | tablet | 02342162 |
| Teva Canada Limited | Teva-Nevirapine | Viramune | nevirapine | 200mg | tablet | 02352893 |

Updated: February 11, 2011